A large scale study of angiotensin II inhibition therapy in an elderly population: The CHANCE study

Vascular Health and Risk Management

Volumn 2, Issue 3, 2006, Pages 317-323

  Asmar, Roland ^a   Nisse Durgeat, Sophie ^b  

^a Cardiovascular Institute   (France)

^b Laboratoires Takeda   (France)

Author keywords

Angiotensin II receptor antagonist; Candesartan cilexetil; CHANCE study; Elderly subject; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGE; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; GENDER; GERIATRIC PATIENT; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; VERTIGO;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 33747752535     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.3.317     Document Type: Article

References (28)

1. Andrawes WF, Bussy C, Belmin J. 2005. Prevention of cardiovascular events in elderly people. Drugs Aging, 22:859-76.
2. Asmar R, Porcellati C, Dusing R. 2004. Switch from ABCD pre-treatment to A-II-A treatment: a multinational open, centrally randomized, prospective parallel group comparison. Drugs Exp Clin Res, 30:153-61.
3. Asmar R, Vol S, Pannier B, et al. 2001. High blood pressure and associated cardiovascular risk factors in France. J Hypertens, 19:1727-32.
4. Berlowitz DR, Ash AS, Hickey EC, et al. 1998. Inadequate management of blood pressure in a hypertensive population. N Engl J Med, 339:1957-63.
5. Chaudhry SI, Krumholz HM, Foody JM. 2004. Systolic hypertension in older person. JAMA, 292:1074-80.
6. Chobanian AV, Bakris GL, Black HR, et al. 2003. The Seventh Report of the Joint National Committee on Preventions, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA, 289:2560-72.
7. Cushman WC, Ford CE, Cutler JA, et al. 2002. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens, 4:393-404.
8. Dahlof B, Lindholm LH, Hansson L et al. 1991. Morbidity and mortality in the Swedish Trial and Old Patients with Hypertension (STOP-Hypertension). Lancet, 265:1281-5.
9. Elmfeldt D, George M, Hubner R, et al. 1997. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens, 11:S49-53.
10. [ESH] Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 21:1011-53.
11. [HAS] Haute Authorité de Santé. 2005. Prise en charge des patients adultes atteints d'hypertension artérielle essentielle. Actualisation des recommendations. Private communication.
12. Kjeldsen SE, Dahlof B, Devereux RB, et al. 2000. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan intervention for endpoint. Am J Hypertens, 13:899-906.
13. Meredith P. 2000. Achieving quality 24-h blood pressure control with candesartan cilexetil. Blood Press Suppl, 1:23-6.
14. Mulrow CD, Cornell JA, Herrera CR, et al. 1994. Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA, 272:1932-8.
15. Neldam S, Forsen B. 2001. Multicentre Study Group. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. Drugs Aging, 18:225-32.
16. O'Brien E, Asmar R, Beilin L, et al. 2003. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens, 21:821-48.
17. Oparil S, Levine JH, Zuschke CA, et al. 1999. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol, 84:289-93.
18. Reif M, White WB, Fagan TC, et al. 1998. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol, 82:961-5.
19. SHEP Cooperative Research Group. 1991. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 265:3255-64.
20. Skoog I, Lithell H, Hansson L, et al. 2005. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on Cognition and Prognosis in the Elderly (SCOPE). Am J Hypertens, 18:1052-9.
21. Staessen JA, Fagard R, Thijs L, et al. 1997. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet, 350:757-64.
22. Thijs L, Hond ED, Nawrot T, et al. 2004. Prevalence, pathophysiology and treatment of isolated systolic hypertension in the elderly. Expert Rev Cardiovasc Ther, 2:761-9.
23. Thomas GN, Chan P, Tomlinson B. 2006. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging, 23:131-55.
24. Trenkwalder P. 2000. Efficacy and tolerability of candesartan cilexetil in special patient groups. Blood Press Suppl, 1:27-30.
25. Trenkwalder P, Elmfeldt D, Hofman A, et al. 2005. The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Press, 14:31-7.
26. Turnbull F. 2003. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 362:1527-35.
27. Vaccarino V, Berger AK, Abramson J, et al. 2001. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am J Cardiol, 88:980-6.
28. Vasan RS, Beiser A, Seshadri S et al. 2002. Residual life time risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA, 287: 1003-10.